1.37

7.03% 0.09

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $1.37, with a volume of 753.25K. It is up +7.03% in the last 24 hours and down -33.82% over the past month.

Previous Close:

$1.28

Open:

$1.25

24h Volume:

753.25K

Relative Volume:

1.00

Market Cap:

$138.38M

Revenue:

$42.51M

Net Income/Loss:

$-116.49M

P/E Ratio:

-1.2232

EPS:

-1.12

Net Cash Flow:

$-120.82M

1W Performance:

-11.04%

1M Performance:

-33.82%

6M Performance:

-80.54%

1Y Performance:

-81.88%

1-Day Range:

$1.23

$1.375

1-Week Range:

$1.23

$1.655

52-Week Range:

$1.23

$12.02

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	1.37	138.38M	42.51M	-116.49M	-120.82M	-1.12
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

Mar 31, 2025

Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 31, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 30, 2025

Mar 29, 2025

Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 29, 2025

Mar 25, 2025

Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire

Mar 25, 2025

Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan

Mar 25, 2025

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com

Mar 24, 2025

Mar 21, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World

Mar 21, 2025

Mar 13, 2025

Tango Therapeutics executive sells shares worth $43,865 - MSN

Mar 13, 2025

Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World

Mar 13, 2025

Mar 10, 2025

Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 07, 2025

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN

Mar 07, 2025

Mar 06, 2025

Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 06, 2025

Feb 28, 2025

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat

Feb 28, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St

Feb 28, 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK

Feb 28, 2025

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Feb 28, 2025

Feb 27, 2025

Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Feb 27, 2025